Richard
  
Aplenc
MD, PhD, MSCE
Email: 
raplenc@mail.med.upenn.edu
Address: 
CTRB Room 4018 3501 Civic Center Blvd
2674267252
Affiliations
Expertise

Dr. Aplenc's research involves molecular epidemiology, pediatric cancer Phase I clinical trials, treatment of pediatric AML, and the use of genetic polymorphism data to predict treatment response to therapeutic interventions, particularly in pediatric cancer therapy.

Appointments
Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2008 – 2011)
Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine (2002 – 2008)
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia (2011– present)
Education
PhD, Epidemiology, University of Pennsylvania (2011)
MSCE, Clinical Epidemiology and Biostatistics, University of Pennsylvania (2002)
MD, University of Virginia (1994)
A.B., Classics, Princeton University (1988)
Selected Publications
Lothstein K., Fisher B. T., Li Y., Seif A., Harris T., Torp K., Kavcic M., Huang Y. S., Rheingold S. R., Aplenc R.. Zoonotic infections in pediatric patients with acute leukemia. Pediatr Blood Cancer. Vol 60(12) . 2013 Dec:E160-2.
Fraser C., Brown P., Megason G., Ahn H. S., Cho B., Kirov I., Frankel L., Aplenc R.,. Open-label Bendamustine Monotherapy for Pediatric Patients With Relapsed or Refractory Acute Leukemia: Efficacy and Tolerability. J Pediatr Hematol Oncol. 2013 Oct:[Epub ahead of print].
de Blank P., Zaoutis T., Fisher B. T., Troxel A., Kim J., Aplenc R.. Trends in Clostridium difficile Infection and Risk Factors for Hospital Acquisition of Clostridium difficile among Children with Cancer.. The Journal of pediatrics. Vol 163(3) . 2013 Sep:699-705e1.
Johnston D. L., Nagarajan R., Caparas M., Schulte F., Cullen P., Aplenc R., Sung L.. Reasons for Non-Completion of Health Related Quality of Life Evaluations in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. PLoS One. Vol 8(9) . 2013 Sep:e74549.
Fisher B. T., Gerber J. S., Leckerman K. H., Seif A. E., Huang Y. S., Li Y., Harris T., Torp K., Rheam D., Shah A., Walker D., Aplenc R.. Variation in Hospital Antibiotic Prescribing Practices for Children with Acute Lymphoblastic Leukemia. Leuk Lymphoma. Vol 54(8) . 2013 Aug:1633-9.
Fisher B.T., Singh S., Huang Y.S., Li Y., Gregory J., Walker D., Seif A.E., Kavcic M., Aplenc R... Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. Pediatr Blood Cancer. 2013 July:[Epub ahead of print].
Kavcic M. Fisher B. T., Seif A. E., Li Y., Huang Y. S., Walker D., Aplenc R.. Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United States.. The Journal of pediatrics. Vol 162(6) . 2013 June:1252-8.
Teachey D. T., Rheingold S. R., Maude S. L., Zugmaier G., Barrett D. M., Seif A. E., Nichols K. E., Suppa E. K., Kalos M., Berg R. A., Fitzgerald J. C., Aplenc R., Gore L., Grupp S. A.. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy.. Blood. Vol 121(26) . 2013 June:5154-7.
Hagleitner M. M., Coenen M. J., Aplenc R., Patiño-Garcia A., Chiusolo P., Gemmati D., De Mattei M., Ongaro A., Krajinovic M., Hoogerbrugge P. M., Vermeulen S. H., Te Loo D. M.. The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. The Pharmacogenomics Journal. 2013 May:[Epub ahead of print].
Kavcic M., Fisher B. T., Li Y., Seif A., Torp K., Walker D. M., Huang Y. S., Lee G. H., Tasian S. K., Vujkovic M., Bagatell R., Aplenc R.. Induction Mortality and Resource Utilization in Children Treated for Acute Myeloid Leukemia at Free-Standing Pediatric Hospitals in the United States. Cancer. Vol 119(10) . 2013 May:916-23.